migalastat (galafold) Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

  • Now
Migalastat (Galafold)-a small molecule drug developed by Amicus Therapeutics that restores the activity of specific mutant forms of α-galactosidase-has been approved for the treatment of Fabry disease in the EU in patients with amenable mutations. Migalastat attaches to certain unstable forms of alpha-galactosidase A, stabilising the enzyme. This allows the enzyme to be transported into areas of the cell where it can break down GL-3. Under the trade name Galafold (formerly known as Amigal), Migalastat is used to treat patients aged 16 years or over with Fabry disease. Because the number of patients with Fabry disease is low, the disease is considered ‘rare’, and the US Food and Drug Administration (FDA) assigned Galafold orphan drug status in 2004, and the European Committee for Medicinal Products for Human Use (CHMP) followed in 2006.   NCATS

More Chemistry

Drug Pricing (per unit)

United States

$1322.8607 - $1766.7850
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-deoxygalactonojirimycin | 1-deoxy-galactonojirimycin | 1-deoxygalacto-nojirimycin | 1-deoxygalactonojirimycin hydrochloride | at1001 deoxyjirimycin | galafold | gr181413a | migalastat | migalastat hcl | migalastat hydrochloride | nb-dgj | nb-dnj | n-butyldeoxygalactonojirimycin | n-butyldeoxygalacto-nojirimycin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue